SCHEMBL2409780

SCHEMBL2409780

COC(=O)C1CC(Oc2cc(F)ccc2N)CN1C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 2/20 0.43
CCNT1 O60563 1/20 0.42
CDK9 P50750 1/20 0.42
HDAC2 Q92769 4/20 0.41
HDAC1 Q13547 3/20 0.41
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
PTPN1 P18031 1/20 0.39
PDE4B Q07343 2/20 0.38
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
KCNH2 Q12809 2/20 0.37
HRH3 Q9Y5N1 2/20 0.37
IDO1 P14902 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
HTRA1 Q92743 1/20 0.36
UCHL1 P09936 1/20 0.36
MCL1 Q07820 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2409775 1.00 P2RX3 (0.43) P2RX3CCNT1CDK9HDAC2HDAC1
SCHEMBL5152159 0.88 CCNT1 (0.44) P2RX3CCNT1CDK9NR1H2NR1H3
SCHEMBL24739225 0.88 CCNT1 (0.44) P2RX3CCNT1CDK9NR1H2NR1H3
SCHEMBL2408809 0.85 P2RX3 (0.41) P2RX3CCNT1CDK9NR1H2NR1H3
SCHEMBL2408811 0.85 P2RX3 (0.41) P2RX3CCNT1CDK9NR1H2NR1H3
SCHEMBL12319154 0.85 P2RX3 (0.41) P2RX3CCNT1CDK9NR1H2NR1H3
SCHEMBL3188809 0.83 NR1H2 (0.43) P2RX3CCNT1CDK9NR1H2NR1H3
SCHEMBL24739556 0.83 NR1H2 (0.43) P2RX3CCNT1CDK9NR1H2NR1H3
SCHEMBL13481242 0.83 NR1H2 (0.43) P2RX3CCNT1CDK9NR1H2NR1H3
SCHEMBL8339060 0.83 NR1H2 (0.43) P2RX3CCNT1CDK9NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648068-B2 Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-11 US disclosed
US-20110212102-A1 HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212102-A1 HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, TNK2, CMPK1 P2RX3 852/4885CCNT1 1005/4885CDK9 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.